ReviewInternational journal of molecular medicine2026
GRP78 dysregulation: A proposed molecular mechanism linking the tumor microenvironment to sepsis susceptibility in patients with cancer (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer are at a significantly higher risk of sepsis, which is associated with substantially increased morbidity and mortality. However, the intrinsic molecular mechanisms driving sepsis susceptibility in this high‑risk population remain unclear. Glucose‑regulated protein 78 (GRP78), the master regulator of endoplasmic reticulum stress, is aberrantly overexpressed and is involved in cell membrane translocation and extracellular release driven by the tumor microenvironment and anticancer therapies. To date, no clinical cohort study has directly established a causal link between GRP78 dysregulation and sepsis incidence or mortality in patients with cancer. The present narrative review therefore relied predominantly on indirect evidence from in vitro studies, animal models and non‑oncologic sepsis cohorts. Despite these limitations, the present study advanced the hypothesis that GRP78 dysregulation may increase sepsis susceptibility through two convergent mechanisms: i) Facilitating pathogen invasion via cell‑surface GRP78, which serves as a critical coreceptor for specific viruses and Mucorales fungi and ii) orchestrating immunosuppression through secreted GRP78‑mediated dampening of innate immune responses. Direct evidence for the function of cell‑surface GRP78 as a bacterial adhesion receptor is limited; its contribution to bacterial sepsis, the predominant clinical form, is primarily indirect and mediated by host inflammatory dysregulation, phagocytic impairment and barrier disruption. The present review provided a preliminary theoretical framework for future investigations into GRP78‑mediated sepsis susceptibility in patients with cancer, with hypothetical implications for risk stratification and targeted interventions, pending dedicated clinical validation in oncology‑specific cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.